Korea Centers for Disease Control and Prevention, Cheongju, Republic of Korea
Copyright © 2015 Korea Centers for Disease Control and Prevention. Published by Elsevier Korea LLC. All rights reserved.
This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-No Derivative Works License (http://creativecommons.org/licenses/by-nc-nd/4.0) which permits non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.
Characteristics | No. of patients |
---|---|
Sex, n (%) | |
Male | 111 (59.7) |
Female | 75 (40.3) |
Age (y), median (IQR) | 55 (42–66) |
≥65y, n (%) | 55 (29.6) |
Case classification, n (%) | |
Healthcare personnel | 25 (13.4) |
Patient | 82 (44.1) |
Caregiver | 61 (32.8) |
Others∗ | 18 (9.7) |
Symptoms at presentation, n (%) | |
Fever/chills | 138 (74.2) |
Cough | 33 (17.7) |
Dyspnea | 10 (5.4) |
Myalgia | 47 (25.3) |
Headache | 16 (8.6) |
GI symptoms† | 24 (12.9) |
Sputum | 14 (7.5) |
Sore throat | 8 (4.3) |
Comorbidities, n (%) | |
Any‡ | 102 (54.8) |
Respiratory disease§ | 23 (12.4) |
Diabetes mellitus | 52 (28.0) |
Cardiac disease∥ | 42 (22.6) |
Chronic kidney disease | 9 (4.8) |
Malignancy | 43 (23.1) |
Known setting of contact, n (%)¶ | |
Healthcare facility | 178 (98.0) |
Household | 1 (0.5) |
Ambulance | 3 (1.5) |
Time from symptom onset to laboratory confirmation in days, median (IQR) | 5 (3–9) |
Time from symptom onset to death in days, median (IQR) | 15 (10–20) |
Outcome as of July 13, 2015, n (%) | |
Recovered | 131 (70.4) |
Ongoing treatment in hospital | 19 (10.2) |
Died | 36 (19.4) |
†Any one or more among the following symptoms: nausea, vomiting, diarrhea, gastric discomfort, loss of appetite.
Patient number | 1 | 14 | 15 | 16 | 76 |
---|---|---|---|---|---|
Infected no. of patients | 28 | 85 | 6 | 23 | 11 |
Age (y) | 68 | 35 | 35 | 41 | 75 |
Sex | Male | Male | Male | Male | Female |
Body mass index | 27 | 30 | 24 | 24 | 19 |
Underlying disease | Hypertension, asthma | No | No | Familial adenomatous polyposis | Diabetes mellitus, multiple myeloma |
Exposed duration (d)∗ | 10 | 9 | 10 | 11 | 2 |
Exposed setting |
GW (27 cases) OPD (1 case) |
ER (78 cases) GW (4 cases) Other (3 cases) |
GW (6 cases) |
GW (22 cases) Other (1 case) |
ER (4 cases) GW (3 cases) Other (4 cases) |
Number of close contacts | 626 | 594 | 304 | 277 | 805 |
Personal protective equipment | No | Intermittent | No | No | No |
Pneumonia† | Present | Present | Present | Present | Present |
Cough | Frequent | Frequent | Rare | Frequent | Rare |
Prognosis | Survived | Survived | Survived | Survived | Expired |
Aerosol-generating procedure | No | No | No | No | No |
Variable |
Univariate logistic regression |
Multivariate logistic regression |
||||
---|---|---|---|---|---|---|
OR | 95%CI | p | OR | 95%CI | p | |
Sex, male | 1.44 | 0.67–3.11 | 0.434 | 1.56 | 0.62–3.91 | 0.33 |
Age, ≥ 65 y | 7.67 | 3.45–17.04 | <0.0001 | 4.86 | 1.90–12.45 | 0.001 |
Case classification, patient | 3.17 | 1.47–6.83 | 0.003 | 0.82 | 0.27–2.50 | 0.73 |
Respiratory disease∗,† | 6.27 | 2.48–15.83 | <0.0001 | 4.90 | 1.64–14.65 | 0.004 |
Diabetes mellitus | 2.91 | 1.436–6.20 | 0.006 | 1.37 | 0.55–3.45 | 0.49 |
Cardiac disease† | 4.43 | 2.02–9.70 | <0.0001 | 2.21 | 0.86–5.67 | 0.09 |
Chronic kidney disease | 5.84 | 1.48–23.0 | 0.012 | 2.30 | 0.44–11.94 | 0.32 |
Malignancy | 2.63 | 1.20–5.76 | 0.015 | 1.92 | 0.75–4.86 | 0.16 |
Characteristics | No. of patients |
---|---|
Sex, n (%) | |
Male | 111 (59.7) |
Female | 75 (40.3) |
Age (y), median (IQR) | 55 (42–66) |
≥65y, n (%) | 55 (29.6) |
Case classification, n (%) | |
Healthcare personnel | 25 (13.4) |
Patient | 82 (44.1) |
Caregiver | 61 (32.8) |
Others | 18 (9.7) |
Symptoms at presentation, n (%) | |
Fever/chills | 138 (74.2) |
Cough | 33 (17.7) |
Dyspnea | 10 (5.4) |
Myalgia | 47 (25.3) |
Headache | 16 (8.6) |
GI symptoms | 24 (12.9) |
Sputum | 14 (7.5) |
Sore throat | 8 (4.3) |
Comorbidities, n (%) | |
Any | 102 (54.8) |
Respiratory disease | 23 (12.4) |
Diabetes mellitus | 52 (28.0) |
Cardiac disease | 42 (22.6) |
Chronic kidney disease | 9 (4.8) |
Malignancy | 43 (23.1) |
Known setting of contact, n (%) | |
Healthcare facility | 178 (98.0) |
Household | 1 (0.5) |
Ambulance | 3 (1.5) |
Time from symptom onset to laboratory confirmation in days, median (IQR) | 5 (3–9) |
Time from symptom onset to death in days, median (IQR) | 15 (10–20) |
Outcome as of July 13, 2015, n (%) | |
Recovered | 131 (70.4) |
Ongoing treatment in hospital | 19 (10.2) |
Died | 36 (19.4) |
Patient number | 1 | 14 | 15 | 16 | 76 |
---|---|---|---|---|---|
Infected no. of patients | 28 | 85 | 6 | 23 | 11 |
Age (y) | 68 | 35 | 35 | 41 | 75 |
Sex | Male | Male | Male | Male | Female |
Body mass index | 27 | 30 | 24 | 24 | 19 |
Underlying disease | Hypertension, asthma | No | No | Familial adenomatous polyposis | Diabetes mellitus, multiple myeloma |
Exposed duration (d) | 10 | 9 | 10 | 11 | 2 |
Exposed setting | GW (27 cases) OPD (1 case) | ER (78 cases) GW (4 cases) Other (3 cases) | GW (6 cases) | GW (22 cases) Other (1 case) | ER (4 cases) GW (3 cases) Other (4 cases) |
Number of close contacts | 626 | 594 | 304 | 277 | 805 |
Personal protective equipment | No | Intermittent | No | No | No |
Pneumonia | Present | Present | Present | Present | Present |
Cough | Frequent | Frequent | Rare | Frequent | Rare |
Prognosis | Survived | Survived | Survived | Survived | Expired |
Aerosol-generating procedure | No | No | No | No | No |
Variable | Univariate logistic regression | Multivariate logistic regression | ||||
---|---|---|---|---|---|---|
OR | 95%CI | p | OR | 95%CI | p | |
Sex, male | 1.44 | 0.67–3.11 | 0.434 | 1.56 | 0.62–3.91 | 0.33 |
Age, ≥ 65 y | 7.67 | 3.45–17.04 | <0.0001 | 4.86 | 1.90–12.45 | 0.001 |
Case classification, patient | 3.17 | 1.47–6.83 | 0.003 | 0.82 | 0.27–2.50 | 0.73 |
Respiratory disease | 6.27 | 2.48–15.83 | <0.0001 | 4.90 | 1.64–14.65 | 0.004 |
Diabetes mellitus | 2.91 | 1.436–6.20 | 0.006 | 1.37 | 0.55–3.45 | 0.49 |
Cardiac disease | 4.43 | 2.02–9.70 | <0.0001 | 2.21 | 0.86–5.67 | 0.09 |
Chronic kidney disease | 5.84 | 1.48–23.0 | 0.012 | 2.30 | 0.44–11.94 | 0.32 |
Malignancy | 2.63 | 1.20–5.76 | 0.015 | 1.92 | 0.75–4.86 | 0.16 |
IQR = interquartile range. Includes visitors, hospital security agents etc. Any one or more among the following symptoms: nausea, vomiting, diarrhea, gastric discomfort, loss of appetite. Any one or more among respiratory diseases, including chronic obstructive pulmonary disease and asthma, diabetes mellitus, cardiac disease, chronic kidney disease, and malignancy. Includes chronic obstructive pulmonary disease and asthma. Includes ischemic heart disease, arrhythmia and heart failure. With exclusion of the index patient and three cases of which the precise setting of contact is unidentified.
ER = emergency room; GW = general ward; OPD = outpatient department. Exposed duration is defined as the period from symptom onset to the date of proper isolation. Pneumonia detected from chest radiograph at the moment of investigation.
Multivariate analysis adjusted by gender, age, and underlying diseases. CI = confidence interval; OR = odds ratio. Includes chronic obstructive pulmonary disease and asthma. Includes ischemic heart disease, dysrhythmia, and heart failure.